Atricure Inc. Stock
Atricure Inc. Stock
Atricure Inc. gained 0.860% compared to yesterday.
Atricure Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 43 € there is a hugely positive potential of 83.76% for Atricure Inc. compared to the current price of 23.4 €.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | 0.860% | 5.455% | 0.000% | -62.581% | -31.765% | -62.581% | -61.653% |
| SI-BONE Inc | 0.000% | 10.833% | 27.885% | -20.359% | -21.302% | - | - |
| Lantheus Holdings Inc | 0.690% | 0.462% | 10.000% | 23.473% | 51.923% | 8.598% | - |
| Cryolife Inc. | 0.570% | 1.705% | -25.417% | -28.968% | -54.161% | 27.857% | -24.153% |
Comments
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
